Arcutis Biotherapeutics (ARQT) said Thursday that data from two phase 3 studies reinforced the efficacy and safety of Zoryve cream for the treatment of mild to moderate atopic dermatitis, a form of eczema.
Zoryve, also known as roflumilast, was approved in July 2024 by the US Food and Drug Administration for the topical treatment of atopic dermatitis in adults and children.
An article in the Journal of American Medical Association Dermatology reported that Zoryve use showed significant improvements across multiple efficacy endpoints and in key secondary endpoints, including itch and 75% reduction in eczema area and severity index score in more than 40% of patients after 4 weeks, the company said.
Arcutis shares were up 1.8% in recent premarket activity.
Price: 10.59, Change: +0.19, Percent Change: +1.83
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。